Apimeds Pharmaceuticals US, Inc Made Headway
Fri, Sep 25, 2026 at 07:48 PM
Apimeds Pharmaceuticals US, Inc (APUS:NYSEMKT) soared at $7.25, representing a gain of 47.4%. On Fri, Sep 25, 2026, APUS:NYSEMKT touched a New 2-Week High of $7.25. The stock got featured on our News Catalysts scanner on Thu, Sep 24, 2026 at 09:23 AM in the 'AGREEMENT' category. From Fri, Sep 11, 2026, the stock recorded 60.00% Up Days and 27.27% Green Days
The stock spiked on Fri, Sep 25, 2026 at $9.14 with a volume of 36M+.
About Apimeds Pharmaceuticals US, Inc (APUS:NYSEMKT)
Apimeds Pharmaceuticals US is a clinical stage biopharmaceutical company that is in the process of developing Apitox, an intradermally administered bee venom-based toxin which potentially exhibits...
Top 10 Gainers:
- Masonglory Limited (MSGY:NASDAQ), 309.64%
- The Marygold Companies, Inc. (MGLD:NYSEMKT), 93.02%
- INLIF Limited (INLF:NASDAQ), 72.88%
- Firefly Neuroscience, Inc. (AIFF:NASDAQ), 68.91%
- Dreamland Limited (TDIC:NASDAQ), 60.41%
- Apimeds Pharmaceuticals US, Inc (APUS:NYSEMKT), 47.36%
- ZW Data Action Technologies Inc. (CNET:NASDAQ), 35.04%
- AIFU Inc. (AIFU:NASDAQ), 32.09%
- ZK International Group Co., Ltd. (ZKIN:NASDAQ), 30.56%
- Brera Holdings PLC (SLMT:NASDAQ), 27.13%